Haitao Bai1, Zhongwei Cao, Chong Deng, Lili Zhou, Chun Wang. 1. Department of Hematology, Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China. baihaitao@gmail.com
Abstract
BACKGROUND: Ara-C is one of the most commonly used drugs in the treatment of AML. However, the development of drug resistance always prevented its further use. It has been shown that miR-181a is associated with the clinical outcome of AML patients. Here, we investigated the possible role of miR-181a in AML Ara-C resistance. METHODS: miR-181a expression was measured by real-time PCR. Cell viability was detected by MTT assay. Protein expressions were measured by western blotting. Caspase activity was examined by fluorescence assay. RESULTS: We found that miR-181a expression was downregulated in the Ara-C-resistant cell line HL-60/Ara-C compared with its parental cell line HL-60. Overexpression of miR-181a in HL-60/Ara-C cells sensitized the cells to Ara-C treatment. Furthermore, Bcl-2 was confirmed as a direct miR-181a target by immunoblot analysis and reporter gene assays. Knockdown of Bcl-2 mimicked the effect of enforced miR-181a expression by reducing cell viability. In addition, the apoptosis pathway was activated by cytochrome C release and caspase 9/caspase 3 activation after miR-181a overexpression. CONCLUSIONS: This study for the first time demonstrated that downregulation of miR-181a and upregulation of Bcl-2 in leukaemia cells confer resistance to Ara-C-based therapy. These results suggest that restoration of miR-181a expression might provide a promising therapeutic in drug resistance of leukaemia.
BACKGROUND:Ara-C is one of the most commonly used drugs in the treatment of AML. However, the development of drug resistance always prevented its further use. It has been shown that miR-181a is associated with the clinical outcome of AMLpatients. Here, we investigated the possible role of miR-181a in AMLAra-C resistance. METHODS: miR-181a expression was measured by real-time PCR. Cell viability was detected by MTT assay. Protein expressions were measured by western blotting. Caspase activity was examined by fluorescence assay. RESULTS: We found that miR-181a expression was downregulated in the Ara-C-resistant cell line HL-60/Ara-C compared with its parental cell line HL-60. Overexpression of miR-181a in HL-60/Ara-C cells sensitized the cells to Ara-C treatment. Furthermore, Bcl-2 was confirmed as a direct miR-181a target by immunoblot analysis and reporter gene assays. Knockdown of Bcl-2 mimicked the effect of enforced miR-181a expression by reducing cell viability. In addition, the apoptosis pathway was activated by cytochrome C release and caspase 9/caspase 3 activation after miR-181a overexpression. CONCLUSIONS: This study for the first time demonstrated that downregulation of miR-181a and upregulation of Bcl-2 in leukaemia cells confer resistance to Ara-C-based therapy. These results suggest that restoration of miR-181a expression might provide a promising therapeutic in drug resistance of leukaemia.
Authors: Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield Journal: Blood Date: 2010-11-02 Impact factor: 22.113
Authors: S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace Journal: Biochem Biophys Res Commun Date: 2005-09-09 Impact factor: 3.575
Authors: Paul E Blower; Ji-Hyun Chung; Joseph S Verducci; Shili Lin; Jong-Kook Park; Zunyan Dai; Chang-Gong Liu; Thomas D Schmittgen; William C Reinhold; Carlo M Croce; John N Weinstein; Wolfgang Sadee Journal: Mol Cancer Ther Date: 2008-01-09 Impact factor: 6.261
Authors: Nikolas Herold; Sean G Rudd; Linda Ljungblad; Kumar Sanjiv; Ida Hed Myrberg; Cynthia B J Paulin; Yaser Heshmati; Anna Hagenkort; Juliane Kutzner; Brent D G Page; José M Calderón-Montaño; Olga Loseva; Ann-Sofie Jemth; Lorenzo Bulli; Hanna Axelsson; Bianca Tesi; Nicholas C K Valerie; Andreas Höglund; Julia Bladh; Elisée Wiita; Mikael Sundin; Michael Uhlin; Georgios Rassidakis; Mats Heyman; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Julian Walfridsson; Sören Lehmann; Dan Grandér; Thomas Lundbäck; Per Kogner; Jan-Inge Henter; Thomas Helleday; Torsten Schaller Journal: Nat Med Date: 2017-01-09 Impact factor: 53.440
Authors: Christopher J Hickey; Sebastian Schwind; Hanna S Radomska; Adrienne M Dorrance; Ramasamy Santhanam; Anjali Mishra; Yue-Zhong Wu; Houda Alachkar; Kati Maharry; Deedra Nicolet; Krzysztof Mrózek; Alison Walker; Anna M Eiring; Susan P Whitman; Heiko Becker; Danilo Perrotti; Lai-Chu Wu; Xi Zhao; Todd A Fehniger; Ravi Vij; John C Byrd; William Blum; L James Lee; Michael A Caligiuri; Clara D Bloomfield; Ramiro Garzon; Guido Marcucci Journal: Blood Date: 2012-10-25 Impact factor: 22.113
Authors: S Emmrich; J E Katsman-Kuipers; K Henke; M E Khatib; R Jammal; F Engeland; F Dasci; C M Zwaan; M L den Boer; L Verboon; J Stary; A Baruchel; V de Haas; A A Danen-van Oorschot; M Fornerod; R Pieters; D Reinhardt; J H Klusmann; M M van den Heuvel-Eibrink Journal: Leukemia Date: 2013-11-25 Impact factor: 11.528